290 research outputs found

    Place, body, light. The Theatre of / Il teatro di Fabrizio Crisafulli. 1991-2022. Updated and augmented edition

    No full text
    Luogo, Corpo e Luce sono i termini sui quali si incentra la ricerca teatrale di Fabrizio Crisafulli. Una ricerca che rimette in discussione dalle fondamenta le pratiche performative, tentando di risalire alla forza originaria del teatro, rivendicandone allo stesso tempo necessità ed efficacia nel contemporaneo. Vi si incontrano danza e architettura, teatro e senso del territorio, performance del corpo e azione poetica della luce. I lavori di Crisafulli, poetici e visionari, ipnotici e sospesi, altamente emozionali e insieme filosofici, producono immaginifici scambi tra archetipi e mondo attuale. Un percorso intenso, che il libro, aggiornamento dell’edizione 2013, ricostruisce attraverso interviste, testimonianze, rassegne critiche, informazioni, testi teorici dell’autore e immagini riguardanti gli spettacoli e le installazioni realizzati dal 1991 al 2022.Place, Body and Light are the terms on which Fabrizio Crisafulli's theatrical research is focused; research which challenges performance practices at their very foundations, in an attempt to reclaim the original potency of theatre and its relevance and effectiveness in contemporary times. This is where dance meets architecture, drama meets territory, and the body meets poetic light. Crisafulli's works are poetic and visionary, hypnotic and deeply emotional, and produce imaginative exchanges between archetypes and the world as it is now. A career of intense research is revealed through interviews, personal accounts, reviews, information, theoretical texts by the author and photos of the performances and installations created between 1991 and 2022

    Multiple frequency functional connectivity in the hand somatosensory network: An EEG study

    No full text
    Objective: To investigate the dynamics of communication within the primary somatosensory neuronal network. Methods: Multichannel EEG responses evoked by median nerve stimulation were recorded from six healthy participants. We investigated the directional connectivity of the evoked responses by assessing the Partial Directed Coherence (PDC) among five neuronal nodes (brainstem, thalamus and three in the primary sensorimotor cortex), which had been identified by using the Functional Source Separation (FSS) algorithm. We analyzed directional connectivity separately in the low (1-200. Hz, LF) and high (450-750. Hz, HF) frequency ranges. Results: LF forward connectivity showed peaks at 16, 20, 30 and 50. ms post-stimulus. An estimate of the strength of connectivity was modulated by feedback involving cortical and subcortical nodes. In HF, forward connectivity showed peaks at 20, 30 and 50. ms, with no apparent feedback-related strength changes. Conclusions: In this first non-invasive study in humans, we documented directional connectivity across subcortical and cortical somatosensory pathway, discriminating transmission properties within LF and HF ranges. Significance: The combined use of FSS and PDC in a simple protocol such as median nerve stimulation sheds light on how high and low frequency components of the somatosensory evoked response are functionally interrelated in sustaining somatosensory perception in healthy individuals. Thus, these components may potentially be explored as biomarkers of pathological conditions. © 2012 International Federation of Clinical Neurophysiology

    Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants

    No full text
    New twelve in silico designed coumarin-based ERα antagonists, namely 3DQ-1a to 3DQ-1е, were synthesized and confirmed as selective ERα antagonists, showing potencies ranging from single-digit nanomolar to picomolar. The hits were confirmed as selective estrogen receptor modulators and validated as antiproliferative agents using MCF-7 breast cancer cell lines exerting from picomolar to low nanomolar potency, at the same time showing no agonistic activity within endometrial cell lines. Their mechanism of action was inspected and revealed to be through the inhibition of the Raf-1/MAPK/ERK signal transduction pathway, preventing hormone-mediated gene expression on either genomic direct or genomic indirect level, and stopping the MCF-7 cells proliferation at G0/G1 phase. In vivo experiments, by means of the per os administration to female Wistar rats with pre-induced breast cancer, distinguished six derivatives, 3DQ-4a, 3DQ-2a, 3DQ-1a, 3DQ-1b, 3DQ-2b, and 3DQ-3b, showing remarkable potency as tumor suppressors endowed with optimal pharmacokinetic profiles and no significant histopathological profiles. The presented data indicate the new compounds as potential candidates to be submitted in clinical trials for breast cancer therapy
    corecore